£64.1 M

Allergy Therapeutics Revenue FY, 2017
Allergy Therapeutics Gross profit (FY, 2017)47.4 M
Allergy Therapeutics Gross profit margin (FY, 2017), %73.9%
Allergy Therapeutics Net income (FY, 2017)-2.5 M
Allergy Therapeutics EBITDA (FY, 2017)109 K
Allergy Therapeutics EBIT (FY, 2017)-1.9 M
Allergy Therapeutics Cash, 30-Jun-201722.1 M
Allergy Therapeutics EV181.8 M

Allergy Therapeutics Revenue

Allergy Therapeutics revenue was £64.14 m in FY, 2017

Embed Graph

Allergy Therapeutics Income Statement

Annual

GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

20.6m23.6m25.7m31.0m37.8m40.8m41.6m41.3m39.3m42.0m43.2m48.5m64.1m

Revenue growth, %

7%3%12%

Cost of goods sold

4.9m6.5m10.1m10.9m13.6m11.2m13.2m13.7m12.0m12.0m12.2m14.1m16.8m

Gross profit

15.8m17.0m15.7m20.2m24.2m29.6m28.3m27.6m27.3m30.0m31.1m34.4m47.4m

Gross profit Margin, %

76%72%61%65%64%73%68%67%70%72%72%71%74%

Operating expense total

18.2m10.4m42.5m35.8m29.3m28.1m28.2m26.5m26.7m28.8m30.3m46.4m49.3m

EBITDA

(25.5m)(14.4m)(3.8m)2.9m1.8m3.0m2.0m2.5m2.0m(10.3m)109.0k

EBITDA margin, %

(99%)(47%)(10%)7%4%7%5%6%5%(21%)0%

EBIT

(2.4m)6.7m(26.8m)(15.6m)(5.1m)1.5m115.0k1.1m668.0k1.2m725.0k(12.0m)(1.9m)

EBIT margin, %

(12%)28%(104%)(50%)(14%)4%0%3%2%3%2%(25%)(3%)

Pre tax profit

(1.9m)(6.1m)(26.3m)(20.2m)(11.4m)(116.0k)(2.3m)640.0k529.0k1.1m654.0k(12.1m)(2.0m)

Income tax expense

2.5m(53.0k)(326.0k)702.0k(349.0k)183.0k104.0k(343.0k)(546.0k)(1.0m)(511.0k)

Net Income

(1.9m)(6.1m)(23.8m)(20.3m)(11.8m)586.0k(2.7m)823.0k633.0k741.0k108.0k(13.1m)(2.5m)

Allergy Therapeutics Balance Sheet

Annual

GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

15.1m23.9m5.7m2.3m4.5m1.0m903.0k1.3m2.0m21.2m23.4m22.1m

Accounts Receivable

2.2m1.8m1.8m2.0m1.7m2.1m2.8m3.1m3.1m2.8m3.1m4.7m4.3m

Inventories

2.7m3.7m4.9m5.8m6.0m6.9m7.1m6.7m6.0m6.5m6.7m7.7m7.5m

Current Assets

21.0m31.1m14.0m11.3m9.4m14.8m14.9m13.0m14.5m14.2m33.8m37.6m37.5m

PP&E

2.1m3.6m5.9m6.9m7.2m8.9m8.8m7.6m7.3m7.0m8.8m9.7m9.7m

Goodwill

3.8m5.0m5.4m

Total Assets

26.7m37.9m23.6m23.2m22.1m29.1m30.6m27.8m29.0m28.4m50.7m56.7m57.2m

Accounts Payable

1.5m1.7m4.6m2.3m3.7m3.9m3.8m2.6m3.1m2.5m2.8m3.1m2.9m

Current Liabilities

6.1m4.9m10.7m8.1m21.8m10.0m11.1m7.7m7.6m6.5m7.4m12.5m14.0m

Non-Current Liabilities

455.0k239.0k4.5m26.4m23.5m15.2m17.3m5.4m6.7m6.8m8.8m13.8m13.2m

Total Debt

2.4m26.0k1.3m288.0k251.0k1.7m1.9m

Total Liabilities

6.6m5.2m15.2m34.5m45.3m25.2m28.5m13.2m14.3m13.3m16.2m26.4m27.2m

Additional Paid-in Capital

73.0k92.0k92.0k92.0k92.0k321.0k321.0k417.0k420.0k420.0k556.0k599.0k604.0k

Retained Earnings

(1.9m)(6.1m)(23.8m)(20.3m)(11.8m)586.0k(2.7m)823.0k633.0k741.0k108.0k(13.1m)(2.5m)

Total Equity

20.1m32.7m8.4m(11.3m)(23.2m)3.9m2.1m14.6m14.7m15.1m34.5m30.3m30.0m

Debt to Equity Ratio

-0.2 x0 x0.1 x0 x0 x0.1 x0.1 x

Debt to Assets Ratio

0.1 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1.3 x1.2 x2.8 x-2.1 x-1 x7.5 x14.3 x1.9 x2 x1.9 x1.5 x1.9 x1.9 x

Allergy Therapeutics Cash Flow

Annual

GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(1.9m)(6.1m)(23.8m)(20.3m)(11.8m)586.0k(2.7m)823.0k633.0k741.0k108.0k(13.1m)(2.5m)

Cash From Operating Activities

15.0k8.1m20.3m19.3m(440.0k)1.7m(2.0m)2.9m2.4m2.2m3.1m(11.8m)178.0k

Cash From Financing Activities

14.1m18.5m2.7m18.6m103.0k4.9m764.0k(2.7m)148.0k20.1m12.5m(188.0k)

Net Change in Cash

13.6m8.8m17.7m3.4m(2.3m)4.6m(3.5m)(1.4m)1.4m1.0m20.5m(792.0k)(2.0m)

Income Taxes Paid

(343.0k)(546.0k)(1.0m)

Allergy Therapeutics Ratios

GBPY, 2017

EV/EBITDA

1.7 k x

EV/EBIT

-95.9 x

EV/CFO

1 k x

Revenue/Employee

135.6k

Debt/Equity

0.1 x

Financial Leverage

1.9 x
Report incorrect company information